Mizuho Reiterates Buy on Iovance Biotherapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Mara Goldstein has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $30.
September 15, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has reiterated a 'Buy' rating on Iovance Biotherapeutics and maintained a price target of $30.
The reiteration of a 'Buy' rating by Mizuho indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $30 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100